

Eric J Kuo

- Affiliate, Department Funds
- Fellow in Graduate Medical Education

Publications

PUBLICATIONS

- **Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations**
Kuo, E., Santiago, V., Tanaka, K., Puram, V., Zhou, C., Tai, J. W., Mannis, G., Majeti, R., Zhang, T. Y.
AMER SOC HEMATOLOGY.2023
- **Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Lai, C., Bhansali, R. S., Kuo, E. J., Mannis, G., Lin, R. J.
2023; 43: e390018
- **Neurotoxicity with blinatumomab in combination with intrathecal methotrexate therapy.** *Leukemia & lymphoma*
On, S., Kuo, E., Lau, K. M.
2022: 1-4
- **Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.** *Blood advances*
Muffy, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., Spiegel, J. Y., Arai, S., Frank, M. J., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, et al
2021; 5 (16): 3147-3151
- **Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.** *Clinical lymphoma, myeloma & leukemia*
Badar, T., Szabo, A., Wadleigh, M., Liedtke, M., Arslan, S., Siebenaller, C., Aldoss, I., Schultz, E., Hefazi, M., Litzow, M. R., Kuo, E., Wang, A., Curran, et al
2020
- **Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience**
Badar, T., Advani, A. S., Liedtke, M., Arslan, S., Khan, M., Aldoss, I., Sienbenaller, C., Schultz, E., Hefazi, M., Shallis, R., Yurkiewicz, I., Podoltsev, N., Patel, et al
ELSEVIER SCIENCE INC.2020: S101–S102
- **Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.** *Cancer*
Badar, T. n., Szabo, A. n., Dinner, S. n., Liedtke, M. n., Burkart, M. n., Shallis, R. M., Yurkiewicz, I. R., Kuo, E. n., Khan, M. A., Balasubramanian, S. n., Yang, J. n., Hefazi, M. n., Podoltsev, et al
2020
- **Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin**
Badar, T., Szabo, A., Wadleigh, M., Liedtke, M., Arslan, S., Siebenaller, C., Aldoss, I., Schultz, E., Hefazi, M., Litzow, M., Kuo, E., Wang, A., Curran, et al
AMER SOC HEMATOLOGY.2019
- **KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma** *JOURNAL OF PATHOLOGY*
Tsang, Y. T., Deavers, M. T., Sun, C. C., Kwan, S., Kuo, E., Malpica, A., Mok, S. C., Gershenson, D. M., Wong, K.
2013; 231 (4): 449-456